Back to research

Research paper

Clinical features associated with a response to ethosuximide in developmental and epileptic encephalopathy with spike wave activation in sleep

Study of ethosuximide as an ASM option in DEE-SWAS. Explores response rates, EEG effects (SWI reduction), tolerability, and position within the DEE-SWAS treatment algorithm.

Indexed context

Ng ACH, et al.

ethosuximidedee-swasasmtreatment2026

Markdown path

content/research/papers/2026-ng-ethosuximide-dee-swas.md

Findings

Study of ethosuximide as an ASM option in DEE-SWAS. Explores response rates, EEG effects (SWI reduction), tolerability, and position within the DEE-SWAS treatment algorithm.

Why it may matter for Levi

Ethosuximide is not currently on Levi's ASM list. If SWAS recurs, ethosuximide is a potential add-on (especially given its relative tolerability in pediatric cohorts). Worth reviewing full text before any ASM escalation discussion.

Paper text

Ng et al. (2026) — Ethosuximide response in DEE-SWAS

Source

  • Epilepsy & Behavior, 2026.

Why in corpus

Ethosuximide is not in Levi's current treatment plan but is a reasonable adjunct for specific DEE-SWAS phenotypes; this paper characterizes which phenotypes respond.

Key findings

  • Identifies clinical features associated with ethosuximide response in DEE-SWAS.
  • Consistent with the older finding that ethosuximide is selectively effective in the atypical-absence-featuring subset of DEE-SWAS, not broadly effective across the whole syndrome.
  • Positions ethosuximide as an adjunctive option for carefully selected patients rather than a first- or second-line standard.

Levi-relevant takeaways

  • Ethosuximide is an option to raise with Levi's epileptologist if steroid durability is limited and the next tiers (benzodiazepines, sulthiame, IVIG, fenfluramine) are exhausted, if Levi's semiology includes absence-like features on repeat prolonged EEG.
  • Current Levi epilepsy semiology does not prominently feature atypical absences; likelihood of meaningful ethosuximide response is modest. Worth noting as an option rather than prioritizing.